Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus-a prospective pilot study

Rheumatology

Volumn 50, Issue 9, 2011, Pages 1640-1644

  Chen, Hua ^a   Zheng, Wenjie ^a   Su, Jinmei ^a   Xu, Dong ^a   Wang, Qian ^a   Leng, Xiaomei ^a   Zhang, Wen ^a   Li, Mengtao ^a   Tang, Fulin ^a   Zhang, Xuan ^a   Zeng, Xiaofeng ^a   Zhao, Yan ^a   Zhang, Fengchun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Rituximab; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

ANTINUCLEAR ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CD19 ANTIGEN; COMPLEMENT COMPONENT C3; CYCLOSPORIN A; CYCLOSPORIN C; DOUBLE STRANDED DNA ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUNG THROMBOSIS; LYMPHOCYTE DEPLETION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY THROMBOCYTOPENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051931207     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker176     Document Type: Article

References (20)

1. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
2. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
3. Jones RB, Tervaert JWC, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
4. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009;123:e159-63.
5. Lee JW, Kim HA, Sung JM, Suh CH. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus. Lupus 2010;19:227-8.
6. Limal N, Cacoub P, Sène D, Guichard I, Piette JC. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 2008;17:69-71.
7. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
8. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2458-66.
9. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG-R, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007; 86:871-7.
10. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.
11. Zheng WJ, Zhang X, Wang Q, Xu D, Zeng XF, Zhang FC. Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe? Ann Rheum Dis 2009;68:1077-8.
12. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
13. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-8.
14. von Bonin M, Oelschlägel U, Radke J et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875-9.
15. Zaja F, Battista ML, Pirrotta MT et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008;93: 930-3.
16. Zaja F, Vianelli N, Volpetti S et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010;85:329-34.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
19. Stasi R, Del Poeta G, Stipa E et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110:2924-30.
20. Suzuki K, Nagasawa H, Kameda H et al. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology 2009;48:198-9.